Matches in SemOpenAlex for { <https://semopenalex.org/work/W2898282980> ?p ?o ?g. }
Showing items 1 to 69 of
69
with 100 items per page.
- W2898282980 endingPage "S638" @default.
- W2898282980 startingPage "S637" @default.
- W2898282980 abstract "Treatment of apical lung tumors with stereotactic body radiation therapy (SBRT) can be challenging due to proximity to the brachial plexus (BP). We retrospectively investigated outcomes after treatment of apical lung tumors to compare the rate of brachial plexopathy (BPX) with what would be estimated based on published protocol-derived BP constraints. Apical lung tumors were defined in this analysis as those whose lung SBRT target had a planning-derived PTV edge <1cm from the anatomic BP. We surveyed an IRB-approved prospective registry of 1,462 patients treated with SBRT for the interval 2003-2017 and included all patients who received definitive or salvage SBRT using dose/fractionation schedules of 50 Gy/5 fx, 60 Gy/5 fx, or 48 Gy/4 fx. Salvage SBRT included patients with local recurrence after conventional fractionation radiotherapy. Per RTOG protocols, the subclavian vein (SCV) ipsilateral to target was contoured as the BP surrogate. In this study, the ipsilateral subclavian artery (SCA), and BP were also contoured to characterize dosimetric differences between structures. Statistical analysis involved repeated measures ANOVA. Sixty-four patients, which includes six patients (9.4%) receiving salvage SBRT, met inclusion criteria (median follow up of 21 months). No significant differences (p=0.77) were observed between maximum point doses to BP, SCV, and SCA. Within one year post-SBRT, two patients (3%) developed BPX (grade 2); both patients had exceeded 32 Gy to the BP and were treated with salvage SBRT. No patient treated with definitive SBRT (91%) developed BP, despite 17 of these exceeding recommended maximum doses. No BPX was observed for patients that exceeded a maximum dose of 32 Gy to the BP, unless they were treated as salvage SBRT. This suggests higher doses to the BP may be considered when clinically required for definitive SBRT. However, salvage SBRT may require more conservative BP constraints than used in the definitive setting." @default.
- W2898282980 created "2018-11-02" @default.
- W2898282980 creator A5000177245 @default.
- W2898282980 creator A5007618026 @default.
- W2898282980 creator A5017950256 @default.
- W2898282980 creator A5062476184 @default.
- W2898282980 creator A5073148665 @default.
- W2898282980 creator A5080419780 @default.
- W2898282980 creator A5091799946 @default.
- W2898282980 date "2018-10-01" @default.
- W2898282980 modified "2023-09-29" @default.
- W2898282980 title "P1.16-27 Using Rates of Clinical Brachial Plexopathy after Lung SBRT to Better Characterize the Tolerance of the Brachial Plexus" @default.
- W2898282980 doi "https://doi.org/10.1016/j.jtho.2018.08.996" @default.
- W2898282980 hasPublicationYear "2018" @default.
- W2898282980 type Work @default.
- W2898282980 sameAs 2898282980 @default.
- W2898282980 citedByCount "0" @default.
- W2898282980 crossrefType "journal-article" @default.
- W2898282980 hasAuthorship W2898282980A5000177245 @default.
- W2898282980 hasAuthorship W2898282980A5007618026 @default.
- W2898282980 hasAuthorship W2898282980A5017950256 @default.
- W2898282980 hasAuthorship W2898282980A5062476184 @default.
- W2898282980 hasAuthorship W2898282980A5073148665 @default.
- W2898282980 hasAuthorship W2898282980A5080419780 @default.
- W2898282980 hasAuthorship W2898282980A5091799946 @default.
- W2898282980 hasBestOaLocation W28982829801 @default.
- W2898282980 hasConcept C126322002 @default.
- W2898282980 hasConcept C126838900 @default.
- W2898282980 hasConcept C141071460 @default.
- W2898282980 hasConcept C2777714996 @default.
- W2898282980 hasConcept C2780387249 @default.
- W2898282980 hasConcept C2781151446 @default.
- W2898282980 hasConcept C2911088228 @default.
- W2898282980 hasConcept C2989005 @default.
- W2898282980 hasConcept C44249647 @default.
- W2898282980 hasConcept C509974204 @default.
- W2898282980 hasConcept C71924100 @default.
- W2898282980 hasConceptScore W2898282980C126322002 @default.
- W2898282980 hasConceptScore W2898282980C126838900 @default.
- W2898282980 hasConceptScore W2898282980C141071460 @default.
- W2898282980 hasConceptScore W2898282980C2777714996 @default.
- W2898282980 hasConceptScore W2898282980C2780387249 @default.
- W2898282980 hasConceptScore W2898282980C2781151446 @default.
- W2898282980 hasConceptScore W2898282980C2911088228 @default.
- W2898282980 hasConceptScore W2898282980C2989005 @default.
- W2898282980 hasConceptScore W2898282980C44249647 @default.
- W2898282980 hasConceptScore W2898282980C509974204 @default.
- W2898282980 hasConceptScore W2898282980C71924100 @default.
- W2898282980 hasIssue "10" @default.
- W2898282980 hasLocation W28982829801 @default.
- W2898282980 hasOpenAccess W2898282980 @default.
- W2898282980 hasPrimaryLocation W28982829801 @default.
- W2898282980 hasRelatedWork W2039831062 @default.
- W2898282980 hasRelatedWork W2095073570 @default.
- W2898282980 hasRelatedWork W2106890942 @default.
- W2898282980 hasRelatedWork W2156028401 @default.
- W2898282980 hasRelatedWork W2159407377 @default.
- W2898282980 hasRelatedWork W2320664076 @default.
- W2898282980 hasRelatedWork W2949600300 @default.
- W2898282980 hasRelatedWork W2978457763 @default.
- W2898282980 hasRelatedWork W3032026340 @default.
- W2898282980 hasRelatedWork W4223636629 @default.
- W2898282980 hasVolume "13" @default.
- W2898282980 isParatext "false" @default.
- W2898282980 isRetracted "false" @default.
- W2898282980 magId "2898282980" @default.
- W2898282980 workType "article" @default.